Delic Labs to present on psychedelics, cannabis extraction at Grow Up Conference and Expo 2022
by CM Staff
Delic Labs received a Health Canada 56 Research Exemption that will allow scientists to perform tests on a number of compounds including MDMA, LSD, DMT, mescaline and 2C-B.
Dr. Markus Roggen, President and CSO, DELIC Labs (CNW Group/Delic Holdings Inc.)
VANCOUVER — Delic Holdings Corp shared details regarding Dr. Markus Roggen, president and chief scientific officer of Delic Labs, and his participation in the upcoming Grow Up Conference and Expo.
Grow Up Conference and Expo
June 20 to 22
Held at the Victoria Conference Centre in British Columbia, the Grow Up Conference and Expo is a three-day event featuring workshops and panels led by hundreds of cannabis-industry experts from around the world. Dr. Roggen will be taking part in the following panels:
Monday, June 20
Introductions to Psychedelics – An Overview
Mitigating Suffering – Can Psychedelic medicine work for you?
The Business of Psychedelics in Canada and abroad
Tuesday, June 21
Making Extraction more Sustainable
Wednesday, June 22
In April, Delic Labs received a Health Canada 56 Research Exemption that will allow scientists to conduct research and perform tests on a number of compounds outside of psychedelic mushrooms, including MDMA, LSD, DMT, mescaline and 2C-B.
Additionally, Delic Labs has received a Health Canada 56 exemption to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc., a wholly-owned subsidiary of Psilobrain Therapeutics Inc. Delic Labs’ latest exemptions enable the company to develop innovative analytical methods for psychedelic research.
